| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 11 Dec 2025 | 8 Dec 2025 |
| Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/12/2025 inter alia to consider and approve 1) To consider and if thought fit approve the issuance of securities of the Company on a preferential basis in accordance with the Companies Act 2013 read with the rules notified thereunder each as amended and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018 as amended and such other acts rules and regulations as may be applicable subject to any regulatory/ statutory approvals as may be required and the approval of the shareholders of the Company. 2) To adopt and approve the Draft Notice of Extra Ordinary General Meeting of the Company. 3) To fix the day date time and venue of Extra Ordinary General Meeting of the Company. 4) To appoint Scrutinizer for conducting E- voting process for Extra Ordinary General Meeting. 5) Any other Matter with the permission of the chair. Submission of outcome of the Board meeting held on 11th December, 2025. (As Per BSE Announcement Dated on:11.12.2025) | ||
| Board Meeting | 13 Nov 2025 | 9 Nov 2025 |
| Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve 1. To Consider and Approve the unaudited standalone financial results for the quarter and half year ended 30th September 2025 along with Limited Review Report of the auditors; 2. Any other matter with the permission of chair. Submission of Outcome of the Board Meeting held on 13th November, 2025. (As Per BSE Announcement Dated on 13.11.2025) | ||
| Board Meeting | 23 Oct 2025 | 23 Oct 2025 |
| Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company in their meeting held on 23rd October, 2025, has approved the appointment of Ms. Sridevi Belide (DIN: 10455373) as an Additional Director (Non Executive Non-Independent) of the Company with effect from 23rd October, 2025 | ||
| Board Meeting | 14 Aug 2025 | 7 Aug 2025 |
| Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve Submission of Prior Intimation of Board Meeting to be held on Thursday 14th August 2025 to transaction the business mentioned in the file attached herewith. (As Per BSE Announcement Dated on: 14/08/2025 Submission of intimation of allotment of equity shares upon conversion of warrants. (As Per BSE Announcement Dated on: 15/08/2025) | ||
| Board Meeting | 24 Jun 2025 | 21 Jun 2025 |
| Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/06/2025 inter alia to consider and approve Submission of Prior Intimation of Board Meeting to be held on Tuesday 24th June 2025 1. To consider and approve the conversion of Warrants into Equity Shares of the Company. 2. Any other matter with the permission of chair. Submission of outcome of board meeting held on Tuesday, 24th June, 2025 (As Per BSE Announcement dated on 24.06.2025) | ||
| Board Meeting | 27 May 2025 | 20 May 2025 |
| Novelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2025 inter alia to consider and approve To Consider and Approve the audited standalone financial results for the quarter and year ended March 31 2025 along with limited review report of the auditors and other items. Submission of intimation of appointment of secretarial auditor of the company. (As Per BSE Announcement dated on 27.05.2025) | ||
| Board Meeting | 12 Apr 2025 | 9 Apr 2025 |
| Inter alia, to consider and approve:- 1. To consider and approve the convening of an EGM for seeking shareholder approval for the confirmation of appointment of Mr. Laxman Samala as Non-Executive Independent Director of the Company. 2. To appoint a scrutinizer for to scrutinize the voting process for the upcoming EGM. 3. Any other item with the approval of the chairman. Submission of outcome of Board Meeting held on 12th April, 2025 (As Per Bse Announcement Dated on 12.04.2025) | ||
| Board Meeting | 12 Feb 2025 | 6 Feb 2025 |
| Trimurthi Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2025 ,inter alia, to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, intimation is hereby given that a meeting of the Board of Directors of the Company will be held on Wednesday, 12th February 2025 at 05:00 P.M. at the Registered office of the Company, inter-alia to discuss the following: 1. To consider, approve and take on record the unaudited Financial Results of the company for the quarter ended 31st December 2024. 2. To consider and take note of Limited Review Report for the quarter ended 31st December 2024. 3. To take note of the Certificate of Whole Time Director & Chief Financial Officer of the Company for the quarter ended 31st December 2024. 4. Any other item with the approval of the chairman. Appointment of Mr. Lakshman Samala as Independent Director and Ms. Bhoomika Choudhary Chief Financial officer. (As Per BSE Announcement dated on 12.02.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.